NEW YORK (GenomeWeb News) – MicroRNA diagnostics company Rosetta Genomics said today that it has received Clinical Laboratory Improvement Amendments certification in three states.
The Rehovot, Israel-based company said that it has passed the survey for CLIA certification in California, Rhode Island, and Maryland to conduct molecular diagnostic tests at its Rosetta Laboratories, bringing the total number of states from which it has received CLIA certification to 48.
The company also said in financial statements filed with the US Securities and Exchange Commission that it could receive up to $17 million from San Diego-based Prometheus Laboratories for research and development, milestone and other payments, and from royalties from the sale of its tests.
Prometheus licensed the US rights to Rosetta Genomics' miRView mets, miRview squamous, and miRview Meso tests in April, and it took an equity stake in the company. Rosetta Genomics said in the SEC filing that Prometheus purchased 2 million of its ordinary shares for $8 million.